Belharra Therapeutics Inc.

Who: Genentech/Repertoire Immune Medicines What: Repertoire will deploy its Decode immune synapse mapping technology to discover novel autoimmune therapeutic targets for Genentech. Why: Repertoir

Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager. The French f

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected